Addititionally there is proof a significant increase in the size of the market for fentanyl-based products for breakthrough cancer pain over the major EU-countries where ProStrakan operates . This market has grown by 45 percent and of that growth, AbstralTM commanded a 61 percent share. Although invoiced product sales to distributors showed a slight decline in the first quarter 2010 compared to the previous quarter, in-market sales of AbstralTM continued showing a strong underlying development of above 40 percent in Q1 2010 compared to Q4 2009 (..The ADVENTRX team is working to initiate a phase 3 clinical trial in sufferers with sickle cell disease and, once that trial starts, we will be the only firm with a fresh chemical entity in phase 3 for the treatment of sickle cell disease. This leadership is thought by us position can serve as a platform for us to make a significant, positive influence in this important region,’ mentioned Brian M. Culley, Chief Executive Officer of ADVENTRX. As can be common for site transitions, there exists a domain name system propagation period where internet service providers direct users to a new site.